Cargando…

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Background Immunotherapy is a proven therapeutic option in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum therapy. At present, there are no published Indian data regarding administration of nivolumab in this setting. Aim The aim of this study is to retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pareek, Ananya, Patel, Apurva A., Kumar, Mukesh, Kuttikat, Philip G., Annadanam, Harshavardhan, Pendse, Shantanu, Mohammed, Naseer, Panchal, Harsha P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273311/ https://www.ncbi.nlm.nih.gov/pubmed/35833038 http://dx.doi.org/10.1055/s-0041-1733317

Ejemplares similares

Impact of nationwide lockdown on cancer care during COVID-19 pandemic: A retrospective analysis from western India
por: Pareek, Ananya, et al.
Publicado: (2021)

Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
por: Du, Yue (Jennifer), et al.
Publicado: (2023)

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wakasaki, Takahiro, et al.
Publicado: (2020)

Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
por: Tanoue, Kenro, et al.
Publicado: (2021)

Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study
por: Vasiliadou, Ifigenia, et al.
Publicado: (2021)

Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma
por: Okamoto, Isaku, et al.
Publicado: (2022)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
por: Minohara, Kiyoshi, et al.
Publicado: (2021)

Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre
por: Saxena, Mohith, et al.
Publicado: (2018)

Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Gogate, Anagha, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Right cervical lymphadenopathy: a rare presentation of metastatic hepatocellular carcinoma
por: Madabhavi, Irappa, et al.
Publicado: (2014)

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
por: Saba, Nabil F., et al.
Publicado: (2019)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
por: Harrington, Kevin J., et al.
Publicado: (2023)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report
por: Bonomo, Pierluigi, et al.
Publicado: (2020)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma
por: Hori, Ryusuke, et al.
Publicado: (2019)

A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
por: Cocks, Kim, et al.
Publicado: (2019)

Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report
por: Locati, Laura Deborah, et al.
Publicado: (2022)

Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases
por: Houessinon, Aline, et al.
Publicado: (2020)

Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance
por: Tahara, Makoto, et al.
Publicado: (2021)

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022)

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
por: Chung, Christine H., et al.
Publicado: (2021)

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
por: Haddad, Robert I., et al.
Publicado: (2023)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis
por: Pei, Rui, et al.
Publicado: (2021)

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer
por: Maleš, Josip, et al.
Publicado: (2021)

Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma
por: Tada, Hiroe, et al.
Publicado: (2020)

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
por: Vos, Joris L., et al.
Publicado: (2021)

A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2022)

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
por: Johnson, Jennifer M, et al.
Publicado: (2023)

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2018)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_4jepivr9n8uc5qvnnrur045hur